Adalta Ltd

AdAlta (ASX:1AD) aims to become a leader in cell therapy for cancer, providing a pathway for innovative cellular immunotherapies for solid cancers originating in Asia, and China particularly, to reach western regulated markets. Subsidiary company, AdCella, in-licenses first in class or best in class assets, establishes manufacturing and generates clinical data in Australia under a US IND at substantially lower cost than in the US. We act as a force multiplier for our Asian partners, enabling them to reach western markets at no cost but while sharing the upside with us. AdAlta also has a portfolio of assets developed using its proprietary i-body technology available for out-licensing, including: 1. AD-214 is a first in class antifibrotic being developed for lung and kidney fibrosis. With two Phase 1 trials complete, it is ready to advance to Phase 2 trials, providing a much needed new option for patients living under a death sentence with degenerative diseases such as Idiopathic Pulmonary Fibrosis. WD-34 is the first anti-body-like molecule to inhibit malaria, babesia and toxoplasma invasion of red blood cells and liver cells across all strains of these parasites, offering the potential to transform seasonal and deployed personnel malaria prophylaxis